Skip to main content
Erschienen in: Neurological Sciences 3/2021

24.07.2020 | Original Article

Which are the factors influencing NIV adaptation and tolerance in ALS patients?

verfasst von: Massimo Russo, Carmen Bonanno, Claudia Profazio, Stefania La Foresta, Cristina Faraone, Andrea Lizio, Gian Luca Vita, Maria Sframeli, Irene Aricò, Paolo Ruggeri, Antonio Toscano, Giuseppe Vita, Christian Lunetta, Sonia Messina

Erschienen in: Neurological Sciences | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Amyotrophic lateral sclerosis (ALS) is a multisystemic disease compromising both the neuromuscular system and the cognitive status. Non-invasive ventilation (NIV) has been shown to improve survival and quality of life in ALS patients with respiratory failure, but scanty literature investigated which are the predictors of NIV tolerance. The aim of this study was to evaluate the impact of functional, cognitive, neurobehavioral, and respiratory status on NIV compliance and tolerance in patients with ALS. We retrospectively evaluated clinical data of ALS patients who consecutively underwent a NIV trial during hospitalization. Cognitive and neurobehavioral assessments have been performed using the Edinburgh Cognitive and Behavioral ALS Screen (ECAS), the Hospital Anxiety and Depression Scale (HADS), the Frontal Assessment Battery (FAB), the Raven’s 47 Colored Progressive Matrices (PM47), and the Neurobehavioral Rating Scale Revised (NRSR). Seventy-two patients (mean age ± SD; 63.9 ± 10.6 years) were included. Patients adapted were 63/72 (87.5%). The average time of adaptation was 7.82 ± 5.27 days. The time required to reach a satisfying NIV adaptation was significantly related to the presence of sialorrhea (p = 0.02), respiratory status (Borg Dyspnoea Scale, p = 0.006, and ALS-FRS-R respiratory subscore, p = 0.03) and behavioral and cognitive impairment (NRSR-F1, p = 0.04, NRSR- F5, p = 0.04). Presence of sialorrhea and neurobehavioral impairment, and absence of respiratory symptoms are negative predictors of NIV adaptation. This study highlights the need of a multidisciplinary patient-tailored approach including cognitive-behavioral assessment and a psychological support program to optimize patient’s training and compliance to NIV.
Literatur
1.
Zurück zum Zitat Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3:17085CrossRef Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3:17085CrossRef
2.
Zurück zum Zitat Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41:118–130CrossRef Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41:118–130CrossRef
3.
Zurück zum Zitat Chiò A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS study group (2011) Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 82:740–746CrossRef Chiò A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS study group (2011) Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 82:740–746CrossRef
4.
Zurück zum Zitat Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, Heverin M, Howard RS, Huisman MHB, Keren N, Leigh PN, Mazzini L, Mora G, Orrell RW, Rooney J, Scott KM, Scotton WJ, Seelen M, Shaw CE, Sidle KS, Swingler R, Tsuda M, Veldink JH, Visser AE, van den Berg LH, Pearce N (2014) Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 13:1108–1113CrossRef Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, Heverin M, Howard RS, Huisman MHB, Keren N, Leigh PN, Mazzini L, Mora G, Orrell RW, Rooney J, Scott KM, Scotton WJ, Seelen M, Shaw CE, Sidle KS, Swingler R, Tsuda M, Veldink JH, Visser AE, van den Berg LH, Pearce N (2014) Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 13:1108–1113CrossRef
5.
Zurück zum Zitat Consonni M, Iannaccone S, Cerami C, Frasson P, Lacerenza M, Lunetta C, Corbo M, Cappa SF (2013) The cognitive and behavioural profile of amyotrophic lateral sclerosis: application of the consensus criteria. Behav Neurol 27:143–153CrossRef Consonni M, Iannaccone S, Cerami C, Frasson P, Lacerenza M, Lunetta C, Corbo M, Cappa SF (2013) The cognitive and behavioural profile of amyotrophic lateral sclerosis: application of the consensus criteria. Behav Neurol 27:143–153CrossRef
6.
Zurück zum Zitat Montuschi A, Iazzolino B, Calvo A, Moglia C, Lopiano L, Restagno G, Brunetti M, Ossola I, Lo Presti A, Cammarosano S, Canosa A, Chiò A (2015) Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry 86:168–173CrossRef Montuschi A, Iazzolino B, Calvo A, Moglia C, Lopiano L, Restagno G, Brunetti M, Ossola I, Lo Presti A, Cammarosano S, Canosa A, Chiò A (2015) Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry 86:168–173CrossRef
7.
Zurück zum Zitat Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, Singleton J, Woolley S, Andrews H, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Koczon-Jaremko BA, Mitsumoto H, ALS COSMOS (2016) Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. Neurology. 86:813–820CrossRef Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, Singleton J, Woolley S, Andrews H, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Koczon-Jaremko BA, Mitsumoto H, ALS COSMOS (2016) Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. Neurology. 86:813–820CrossRef
8.
Zurück zum Zitat Benbrika S, Desgranges B, Eustache F, Viader F (2019) Cognitive, emotional and psychological manifestations in amyotrophic lateral sclerosis at baseline and overtime: a review. Front Neurosci 13:951CrossRef Benbrika S, Desgranges B, Eustache F, Viader F (2019) Cognitive, emotional and psychological manifestations in amyotrophic lateral sclerosis at baseline and overtime: a review. Front Neurosci 13:951CrossRef
9.
Zurück zum Zitat Aboussouan LS, Mireles-Cabodevila E (2013) Respiratory support in patients with amyotrophic lateral sclerosis. Respir Care 58:1555–1558CrossRef Aboussouan LS, Mireles-Cabodevila E (2013) Respiratory support in patients with amyotrophic lateral sclerosis. Respir Care 58:1555–1558CrossRef
10.
Zurück zum Zitat Radunovic A, Annane D, Rafiq MK, Brassington R, Mustfa N (2017) Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 10:CD004427PubMed Radunovic A, Annane D, Rafiq MK, Brassington R, Mustfa N (2017) Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 10:CD004427PubMed
11.
Zurück zum Zitat Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ (2006) Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 5:140–147CrossRef Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ (2006) Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 5:140–147CrossRef
12.
Zurück zum Zitat Lechtzin N, Scott Y, Busse AM, Clawson LL, Kimball R, Wiener CM (2007) Early use of non-invasive ventilation prolongs survival in subjects with ALS. Amyotroph Lateral Scler 8:185–188CrossRef Lechtzin N, Scott Y, Busse AM, Clawson LL, Kimball R, Wiener CM (2007) Early use of non-invasive ventilation prolongs survival in subjects with ALS. Amyotroph Lateral Scler 8:185–188CrossRef
13.
Zurück zum Zitat Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luís ML (1995) Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci 129(Suppl):19–26CrossRef Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luís ML (1995) Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci 129(Suppl):19–26CrossRef
14.
Zurück zum Zitat Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T (1999) Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 164:82–88CrossRef Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T (1999) Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 164:82–88CrossRef
15.
Zurück zum Zitat Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H (1997) Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med 127:450–453CrossRef Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H (1997) Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med 127:450–453CrossRef
16.
Zurück zum Zitat Lo Coco D, Marchese S, Pesco MC, La Bella V, Piccoli F, Lo Coco A (2006) Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival. Neurology 67:761–765CrossRef Lo Coco D, Marchese S, Pesco MC, La Bella V, Piccoli F, Lo Coco A (2006) Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival. Neurology 67:761–765CrossRef
17.
Zurück zum Zitat Lyall RA, Donaldson N, Fleming T, Wood C, Newsom-Davis I, Polkey MI, Leigh PN, Moxham J (2001) A prospective study of quality of life in ALS patients treated with noninvasive ventilation. Neurology 57:153–156CrossRef Lyall RA, Donaldson N, Fleming T, Wood C, Newsom-Davis I, Polkey MI, Leigh PN, Moxham J (2001) A prospective study of quality of life in ALS patients treated with noninvasive ventilation. Neurology 57:153–156CrossRef
18.
Zurück zum Zitat Bourke SC, Bullock RE, Williams TL, Shaw PJ, Gibson GJ (2003) Noninvasive ventilation in ALS: indications and effect on quality of life. Neurology 61:171–177CrossRef Bourke SC, Bullock RE, Williams TL, Shaw PJ, Gibson GJ (2003) Noninvasive ventilation in ALS: indications and effect on quality of life. Neurology 61:171–177CrossRef
19.
Zurück zum Zitat Gruis KL, Brown DL, Schoennemann A, Zebarah VA, Feldman EL (2005) Predictors of noninvasive ventilation tolerance in patients with amyotrophic lateral sclerosis. Muscle Nerve 32:808–811CrossRef Gruis KL, Brown DL, Schoennemann A, Zebarah VA, Feldman EL (2005) Predictors of noninvasive ventilation tolerance in patients with amyotrophic lateral sclerosis. Muscle Nerve 32:808–811CrossRef
20.
Zurück zum Zitat Volanti P, Cibella F, Sarvà M, De Cicco D, Spanevello A, Mora G, La Bella V (2011) Predictors of non-invasive ventilation tolerance in amyotrophic lateral sclerosis. J Neurol Sci 303:114–118CrossRef Volanti P, Cibella F, Sarvà M, De Cicco D, Spanevello A, Mora G, La Bella V (2011) Predictors of non-invasive ventilation tolerance in amyotrophic lateral sclerosis. J Neurol Sci 303:114–118CrossRef
21.
Zurück zum Zitat Aboussouan LS, Khan SU, Banerjee M, Arroliga AC, Mitsumoto H (2001) Objective measures of the efficacy of noninvasive positive-pressure ventilation in amyotrophic lateral sclerosis. Muscle Nerve 24:403–409CrossRef Aboussouan LS, Khan SU, Banerjee M, Arroliga AC, Mitsumoto H (2001) Objective measures of the efficacy of noninvasive positive-pressure ventilation in amyotrophic lateral sclerosis. Muscle Nerve 24:403–409CrossRef
22.
Zurück zum Zitat Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293–299CrossRef Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293–299CrossRef
23.
Zurück zum Zitat Morelot-Panzini C, Bruneteau G, Gonzalez-Bermejo J (2019) NIV in amyotrophic lateral sclerosis: the ‘when’ and ‘how’ of the matter. Respirology 24:521–530CrossRef Morelot-Panzini C, Bruneteau G, Gonzalez-Bermejo J (2019) NIV in amyotrophic lateral sclerosis: the ‘when’ and ‘how’ of the matter. Respirology 24:521–530CrossRef
24.
Zurück zum Zitat Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:13–21CrossRef Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:13–21CrossRef
25.
Zurück zum Zitat Carlesimo GA, Caltagirone C, Gainotti G (1996) The mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 36:378–384CrossRef Carlesimo GA, Caltagirone C, Gainotti G (1996) The mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 36:378–384CrossRef
26.
Zurück zum Zitat Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML, Forapani E, Russo A, Nichelli P (2005) The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 26:108–116CrossRef Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML, Forapani E, Russo A, Nichelli P (2005) The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 26:108–116CrossRef
27.
Zurück zum Zitat Abrahams S, Newton J, Niven E, Foley J, Bak TH (2014) Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 15:9–14CrossRef Abrahams S, Newton J, Niven E, Foley J, Bak TH (2014) Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 15:9–14CrossRef
28.
Zurück zum Zitat Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370CrossRef Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370CrossRef
29.
Zurück zum Zitat Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52:69–77CrossRef Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52:69–77CrossRef
30.
Zurück zum Zitat Vanier M, Mazaux JM, Lambert J, Dassa C, Levin HS (2000) Assessment of neuropsychologic impairments after head injury: interrater reliability and factorial and criterion validity of the Neurobehavioral Rating Scale-Revised. Arch Phys Med Rehabil 81:796–806PubMed Vanier M, Mazaux JM, Lambert J, Dassa C, Levin HS (2000) Assessment of neuropsychologic impairments after head injury: interrater reliability and factorial and criterion validity of the Neurobehavioral Rating Scale-Revised. Arch Phys Med Rehabil 81:796–806PubMed
31.
Zurück zum Zitat Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, Force AET (2005) Standardisation of spirometry. Eur Respir J 26:319–338CrossRef Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, Force AET (2005) Standardisation of spirometry. Eur Respir J 26:319–338CrossRef
32.
Zurück zum Zitat Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J, Initiative ERSGLF (2012) Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 40:1324–1343CrossRef Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J, Initiative ERSGLF (2012) Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 40:1324–1343CrossRef
33.
Zurück zum Zitat Wilson SH, Cooke NT, Edwards RH, Spiro SG (1984) Predicted normal values for maximal respiratory pressures in caucasian adults and children. Thorax 39:535–538CrossRef Wilson SH, Cooke NT, Edwards RH, Spiro SG (1984) Predicted normal values for maximal respiratory pressures in caucasian adults and children. Thorax 39:535–538CrossRef
34.
Zurück zum Zitat Kendrick KR, Baxi SC, Smith RM (2000) Usefulness of the modified 0-10 Borg scale in assessing the degree of dyspnea in patients with COPD and asthma. J Emerg Nurs 26:216–222CrossRef Kendrick KR, Baxi SC, Smith RM (2000) Usefulness of the modified 0-10 Borg scale in assessing the degree of dyspnea in patients with COPD and asthma. J Emerg Nurs 26:216–222CrossRef
35.
Zurück zum Zitat Maldonado G, Greenland S (1993) Simulation study of confounder-selection strategies. Am J Epidemiol 138:923–936CrossRef Maldonado G, Greenland S (1993) Simulation study of confounder-selection strategies. Am J Epidemiol 138:923–936CrossRef
36.
Zurück zum Zitat Copper A, Weekes TJ (1983) Data, models, and statistical analysis, Rowman & Littlefield, pp 50-51. Copper A, Weekes TJ (1983) Data, models, and statistical analysis, Rowman & Littlefield, pp 50-51.
37.
Zurück zum Zitat Tysnes O-B (2008) Treatment of sialorrhea in amyotrophic lateral sclerosis. Acta Neurol Scand 188:77–81CrossRef Tysnes O-B (2008) Treatment of sialorrhea in amyotrophic lateral sclerosis. Acta Neurol Scand 188:77–81CrossRef
38.
Zurück zum Zitat Garuti G, Rao F, Ribuffo V, Sansone VA (2019) Sialorrhea in patients with ALS: current treatment options. Degener Neurol Neuromuscul Dis 9:19–26PubMedPubMedCentral Garuti G, Rao F, Ribuffo V, Sansone VA (2019) Sialorrhea in patients with ALS: current treatment options. Degener Neurol Neuromuscul Dis 9:19–26PubMedPubMedCentral
39.
Zurück zum Zitat Kontis TC, Johns ME (2006) Anatomy and physiology of the salivary glands. In: Bailay BJ (ed) Head and Neck Surgery Otolaryngology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, pp 531–539 Kontis TC, Johns ME (2006) Anatomy and physiology of the salivary glands. In: Bailay BJ (ed) Head and Neck Surgery Otolaryngology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, pp 531–539
40.
Zurück zum Zitat Chiò A, Ilardi A, Cammarosano S, Moglia C, Montuschi A, Calvo A (2012) Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV. Neurology 78:1085–1089CrossRef Chiò A, Ilardi A, Cammarosano S, Moglia C, Montuschi A, Calvo A (2012) Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV. Neurology 78:1085–1089CrossRef
41.
Zurück zum Zitat Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society (1999) Am J Respir Crit Care Med 159:321-340 Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society (1999) Am J Respir Crit Care Med 159:321-340
42.
Zurück zum Zitat Manera U, Torrieri MC, Moglia C, Viglione M, Daviddi MAR, Matteoni E, Solero L, Palumbo F, Vasta R, Canosa A, D’Ovidio F, Focaraccio L, Mattei A, Mora G, Calvo A, Chiò A (2020) The role of arterial blood gas analysis (ABG) in amyotrophic lateral sclerosis respiratory monitorin. J Neurol Neurosurg Psychiatry 2020 Manera U, Torrieri MC, Moglia C, Viglione M, Daviddi MAR, Matteoni E, Solero L, Palumbo F, Vasta R, Canosa A, D’Ovidio F, Focaraccio L, Mattei A, Mora G, Calvo A, Chiò A (2020) The role of arterial blood gas analysis (ABG) in amyotrophic lateral sclerosis respiratory monitorin. J Neurol Neurosurg Psychiatry 2020
Metadaten
Titel
Which are the factors influencing NIV adaptation and tolerance in ALS patients?
verfasst von
Massimo Russo
Carmen Bonanno
Claudia Profazio
Stefania La Foresta
Cristina Faraone
Andrea Lizio
Gian Luca Vita
Maria Sframeli
Irene Aricò
Paolo Ruggeri
Antonio Toscano
Giuseppe Vita
Christian Lunetta
Sonia Messina
Publikationsdatum
24.07.2020
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 3/2021
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04624-x

Weitere Artikel der Ausgabe 3/2021

Neurological Sciences 3/2021 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.